Text Size

The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

This study has been completed.
Sponsor:
Collaborator:
University of Copenhagen
Information provided by:
University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier:
NCT00732602
First received: August 11, 2008
Last updated: February 12, 2009
Last verified: February 2009
History of Changes
  Purpose

The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.


Condition Intervention
Diabetes Mellitus
 Other: GIP-infusion
Other: Sodium-chloride
Other: GLP-2 infusion

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Official Title: The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University Hospital, Gentofte, Copenhagen:

Primary Outcome Measures:
  • plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min. [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: January 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: B
GLP-2 infusion
 Other: GLP-2 infusion
Placebo Comparator: C
Sodium-chloride infusion
 Other: Sodium-chloride
Active Comparator: A
GIP-infusion
 Other: GIP-infusion

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Caucasians over 18 years with type 1 diabetes (WHO criteria)
  • Arginine test without rise in plasma C-peptide
  • Normal blood Hemoglobin
  • Informed consent

Exclusion Criteria:

  • Liver disease
  • Diabetic nephropathy
  • Treatment with medications unpausable for 12 hours
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00732602

Locations
Denmark
University Hospital, Gentofte
Hellerup, Capital Region, Denmark, 2900
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
University of Copenhagen
  More Information

No publications provided

Responsible Party: Mikkel Christensen MD, University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier: NCT00732602     History of Changes
Other Study ID Numbers: H-D-2007-0058
Study First Received: August 11, 2008
Last Updated: February 12, 2009
Health Authority: Denmark: Ethics Committee

Keywords provided by University Hospital, Gentofte, Copenhagen:
Glucagon
Glucose-dependent Insulinotropic Polypeptide
Glucagon-Like peptide 2

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide 1
 Glucagon
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Gastrointestinal Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 19, 2013